// App-Quantinova.ai

: BLINATUMOMAB USE DURING CONSOLIDATION IN ADULT PATIENTS WITH HIGH-RISK, PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF THE BLIN01 TRIAL.

Researchers

Presenter

  • Josep Maria Ribera

Principal Investigators

  • Santiago Mercadal

  • Pere Barba

  • Pau Montesinos

  • Maria Jose Moreno

  • Jordi Esteve

  • Rodrigo Martino

  • Pilar Martnez

  • Maria Luz Amigo

  • Natalia Alonso

  • Jos Gonzlez-Campos

  • Teresa Bernal

  • Jess Maria Hernndez-Rivas

  • Juana Ciudad

  • Susana Barrena

  • Alberto Orfao

Medical Centers

  • ICO Hospital Universitario Germans Trias i Pujol, Josep Carreras Research Institut, Universitat Autònoma de Barcelona,Badalona,Spain

  • ICO-Hospital Duran i Reynals, LHospitalet de Llobregat, Spain

  • Hospital Universitario del Mar, Barcelona, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Hospital Clínico de Málaga,Málaga,Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Hospital de Sant Pau y Santa Creu, Barcelona, Spain

  • Hospital Doce de Octubre, Madrid, Spain

  • Hospital Morales Meseguer, Murcia, Spain

  • Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Hospital Central de Asturias, Oviedo, Spain

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Histone-lysine N-methyltransferase 2A

  • Lymphocyte count

  • White Blood Cell

Drug/Treatment

  • Blinatumomab

  • Methotrexate

  • Asparaginase

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03523429

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved